Zixuan Gao, Jiachen Zhang, Kejian Li, Yixiang Sun, Xudong Wu, Guoqi Zhang, Rongrong Liu, Rui Liu, Dongmei Zhao and Maosheng Cheng
RSC Med. Chem., 2024,15, 492-505
Abstract
We designed and synthesised a series of novel CYP51 inhibitors. Three rounds of structural optimisation and modification obtained compound C6 which showed superior antifungal activity.
Hans J. Oh, John D. Sears, Bose Muthu Ramalingam, Rahman Shah Zaib Saleem, Zachary W. Davis-Gilbert, Mohammed Anwar Hossain, Stella R. Moorman, Durbadal Ohja, Sabian A. Martinez, Jane E. Burdick, Rafael M. Couñago, Nathaniel J. Moorman, Mark T. Heise, Matthew H. Todd and Timothy M. Willson
RSC Med. Chem., 2026, Advance Article
Abstract
Spirodioxolanes were identified as a new series of direct-acting nsP2 helicase inhibitors with activity against alphaviruses. Analogs such as 6b maintained activity against viral mutants with resistance to first-generation nsP2 helicase inhibitors.
Jingwen Huo, Jizhen Xiao, Yushi Zhang, Xinhui Qiu, Xuechen Huang, Ge Wang, Jianhao Wang, Kuancheng Liu and Jimin Xu
RSC Med. Chem., 2025,16, 3158-3173
Abstract
A series of salicylamide derivatives have been designed, synthesized, and evaluated as potent anti-HBV agents, with preliminary mechanistic insights.
Kejian Li, Guoqi Zhang, Wenzhan Hao, Jinming Liu, Yixiang Sun, Zixuan Gao, Zirui Luo, Rui Liu, Nian Liu, Haoyu Zhang, Xudong Wu, Dongmei Zhao and Maosheng Cheng
RSC Med. Chem., 2025,16, 6173-6189
Abstract
Overall design idea of new 2-phenylthiazole CYP51 inhibitors.
Mariam Omara, Mohamed Hagras, Mohamed M. Elsebaie, Nader S. Abutaleb, Hanzada T. Nour El-Din, Maria O. Mekhail, Ahmed S. Attia, Mohamed N. Seleem, Marwa T. Sarg and Abdelrahman S. Mayhoub
RSC Adv., 2023,13, 19695-19709
Abstract
Twenty-three compounds of novel phenylthiazole derivatives were synthesized utilizing the Suzuki coupling reaction. Antibacterial activity in an in vivo model against MRSA USA300 was evaluated, as it reduced the burden of MRSA USA300 in skin-infected mice.